$CTSO
Cytosorbents Corp Stock $ctso

$ctso Overview Financials Valuation SEC Filings Company Website

2018 Q4 Form 10-Q Financial Statement

#000114420418057624 Filed on November 06, 2018

Income Statement

Concept	2018 Q4	2018 Q3	2017 Q3
Revenue	$6.081M	$5.743M	$3.824M
YoY Change	30.86%	50.17%	58.57%
Cost Of Revenue	$2.080M	$2.053M	$1.517M
YoY Change	63.78%	35.32%	57.37%
Gross Profit	$3.998M	$3.690M	$2.307M
YoY Change	18.21%	59.93%	59.37%
Gross Profit Margin	65.74%	64.26%	60.34%
Selling, General & Admin	$7.160M	$4.041M	$3.575M
YoY Change	50.1%	13.03%	67.01%
% of Gross Profit	179.11%	109.5%	154.93%
Research & Development	$2.420M	$1.943M	$643.2K
YoY Change	0.0%	202.15%	-45.13%
% of Gross Profit	60.54%	52.66%	27.87%
Depreciation & Amortization	$130.0K	$140.0K	$60.00K
YoY Change	116.67%	133.33%	50.0%
% of Gross Profit	3.25%	3.79%	2.6%
Operating Expenses	$9.590M	$6.401M	$4.456M
YoY Change	33.57%	43.63%	24.07%
Operating Profit	-$5.585M	-$2.711M	-$2.149M
YoY Change	46.78%	26.13%	0.23%
Interest Expense	-$440.0K	-$185.2K	-$253.8K
YoY Change	2100.0%	-27.01%	116.26%
% of Operating Profit
Other Income/Expense, Net		-$294.1K	$94.77K
YoY Change		-410.39%	-315.83%
Pretax Income	-$6.020M	-$3.005M	-$2.054M
YoY Change	57.59%	46.27%	-6.12%
Income Tax	-$620.0K	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$5.400M	-$3.005M	-$2.054M
YoY Change	71.43%	46.27%	-6.12%
Net Earnings / Revenue	-88.8%	-52.32%	-53.72%
Basic Earnings Per Share
Diluted Earnings Per Share	-$170.4K	-$95.82K	-$72.67K
COMMON SHARES
Basic Shares Outstanding	31.65M shares	31.46M shares	28.13M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q4	2018 Q3	2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$22.40M	$24.90M	$15.40M
YoY Change	29.48%	61.69%	140.63%
Cash & Equivalents	$22.37M	$24.91M	$15.40M
Short-Term Investments
Other Short-Term Assets	$1.100M	$600.0K	$500.0K
YoY Change	175.0%	20.0%	150.0%
Inventory	$833.1K	$779.4K	$1.100M
Prepaid Expenses
Receivables	$3.943M	$3.643M	$2.400M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$28.26M	$29.95M	$19.40M
YoY Change	36.28%	54.38%	113.19%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.730M	$1.677M	$1.000M
YoY Change	23.32%	67.7%	66.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.753M	$2.622M	$1.800M
YoY Change	40.39%	45.67%	50.0%
Total Long-Term Assets	$5.933M	$4.299M	$2.832M
YoY Change	76.36%	51.79%	57.35%
TOTAL ASSETS
Total Short-Term Assets	$28.26M	$29.95M	$19.40M
Total Long-Term Assets	$5.933M	$4.299M	$2.832M
Total Assets	$34.20M	$34.25M	$22.20M
YoY Change	41.88%	54.28%	103.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.486M	$1.859M	$1.300M
YoY Change	19.4%	43.03%	85.71%
Accrued Expenses	$479.8K	$2.400M	$1.500M
YoY Change	54.66%	60.0%	0.0%
Deferred Revenue	$42.22K	$35.11K
YoY Change	38.97%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$666.7K	$0.00	$3.000M
YoY Change	-83.33%	-100.0%	620.0%
Total Short-Term Liabilities	$6.917M	$4.261M	$5.778M
YoY Change	-11.87%	-26.25%	15.56%
LONG-TERM LIABILITIES
Long-Term Debt	$9.275M	$9.917M	$6.966M
YoY Change	54.78%	42.36%	55.51%
Other Long-Term Liabilities	$1.100M
YoY Change
Total Long-Term Liabilities	$9.275M	$9.917M	$6.966M
YoY Change	54.78%	42.36%	55.51%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.917M	$4.261M	$5.778M
Total Long-Term Liabilities	$9.275M	$9.917M	$6.966M
Total Liabilities	$17.26M	$14.18M	$12.74M
YoY Change	24.72%	11.25%	34.45%
SHAREHOLDERS EQUITY
Retained Earnings	-$169.5M	-$164.1M	-$149.2M
YoY Change	11.3%	10.03%
Common Stock	$31.77K	$31.63K	$28.48K
YoY Change	9.66%	11.07%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$16.93M	$20.07M	$9.474M
YoY Change
Total Liabilities & Shareholders Equity	$34.20M	$34.25M	$22.22M
YoY Change	41.88%	54.15%	103.84%

Cashflow Statement

Concept	2018 Q4	2018 Q3	2017 Q3
OPERATING ACTIVITIES
Net Income	-$5.400M	-$3.005M	-$2.054M
YoY Change	71.43%	46.27%	-6.12%
Depreciation, Depletion And Amortization	$130.0K	$140.0K	$60.00K
YoY Change	116.67%	133.33%	50.0%
Cash From Operating Activities	-$2.710M	-$2.630M	-$2.180M
YoY Change	560.98%	20.64%	-11.74%
INVESTING ACTIVITIES
Capital Expenditures	-$320.0K	-$280.0K	-$540.0K
YoY Change	-44.83%	-48.15%	184.21%
Acquisitions
YoY Change
Other Investing Activities	$0.00		$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$320.0K	-$280.0K	-$540.0K
YoY Change	-44.83%	-48.15%	-1000.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	480.0K	2.570M	1.690M
YoY Change	-83.45%	52.07%	1590.0%
NET CHANGE
Cash From Operating Activities	-2.710M	-2.630M	-2.180M
Cash From Investing Activities	-320.0K	-280.0K	-540.0K
Cash From Financing Activities	480.0K	2.570M	1.690M
Net Change In Cash	-2.550M	-340.0K	-1.030M
YoY Change	-233.51%	-66.99%	-55.41%
FREE CASH FLOW
Cash From Operating Activities	-$2.710M	-$2.630M	-$2.180M
Capital Expenditures	-$320.0K	-$280.0K	-$540.0K
Free Cash Flow	-$2.390M	-$2.350M	-$1.640M
YoY Change	-1505.88%	43.29%	-28.07%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.39
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24911264	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17321862	USD
CY2018Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3642510	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2205859	USD
CY2018Q3	us-gaap	Inventory Net InventoryNet	779425	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	795657	USD
CY2018Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	617119	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	415962	USD
CY2018Q3	us-gaap	Assets Current AssetsCurrent	29950318	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	20739340	USD
CY2018Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1677049	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1402782	USD
CY2018Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2622104	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1961185	USD
CY2018Q3	us-gaap	Assets Assets	34249471	USD
CY2017Q4	us-gaap	Assets Assets	24103307	USD
CY2018Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1859328	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1244411	USD
CY2018Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2017Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	4000000	USD
CY2018Q3	ctso	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	2401975	USD
CY2017Q4	ctso	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	2603920	USD
CY2018Q3	us-gaap	Liabilities Current LiabilitiesCurrent	4261303	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7848331	USD
CY2018Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	9917439	USD
CY2017Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	5992141	USD
CY2018Q3	us-gaap	Liabilities Liabilities	14178742	USD
CY2017Q4	us-gaap	Liabilities Liabilities	13840472	USD
CY2018Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q3	us-gaap	Common Stock Value CommonStockValue	31633	USD
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	28974	USD
CY2018Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	184089635	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	162907482	USD
CY2018Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	70097	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-360985	USD
CY2018Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-164120636	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-152312636	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	20070729	USD
CY2018Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	34249471	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	24103307	USD
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	159998	USD
CY2017Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	151872	USD
CY2018Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	390497	USD
CY2017Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	528039	USD
CY2018Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	228930	USD
CY2017Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	115746	USD
CY2018Q3	us-gaap	Advertising Expense AdvertisingExpense	40000	USD
CY2017Q3	us-gaap	Advertising Expense AdvertisingExpense	45000	USD
	us-gaap	Advertising Expense AdvertisingExpense	126000	USD
	us-gaap	Advertising Expense AdvertisingExpense	132000	USD
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35	pure
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3578538	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1428175	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	55324	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	800	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	719610	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4230979	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.64
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.98
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.57
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	2.88
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.78
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.90
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y3M18D
	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Granted In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm	P9Y6M
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y3M18D
CY2018Q3	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	4230979	shares
CY2018Q3	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	5.90
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P7Y3M18D
CY2018Q3	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	2501456	shares
CY2018Q3	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	4.82
CY2017Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	1070959	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	35326	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	734285	shares
CY2018Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	1729523	shares
CY2017Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	0.70
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.83
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	2.43
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	3.41
CY2018Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	4.52
CY2015Q3	ctso	Aggregate Registered Amount For Offerings AggregateRegisteredAmountForOfferings	150000000	USD
CY2017Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10300000	USD
CY2014Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	4.50
CY2017	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	335731	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0209	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0300	pure
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	12.90
CY2018Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	926000	USD
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	531900	shares
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	668550	shares
CY2018Q3	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	0	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	2113000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	10262835	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2863739	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	13916963	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	431082	USD
	ctso	Stock Issued During Period Value Stock Cash Options Exercised StockIssuedDuringPeriodValueStockCashOptionsExercised	1940711	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	0	USD
	ctso	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised	0	USD
	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	545693	USD
	ctso	Stock Issued During Period Value Stock Cash Warrants Exercised StockIssuedDuringPeriodValueStockCashWarrantsExercised	1280706	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	256794	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	161688	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-785951	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8132538	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6051221	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	495526	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	579944	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	701306	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	516203	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1196832	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1096147	USD
CY2018Q3	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	2381031	USD
CY2017Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	1267459	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	73286	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	56268	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	16722	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	3897	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2863739	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1851020	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-544177	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	1221334	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1518237	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	803348	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-14259	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	227882	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	209683	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	8528	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	269511	USD
CY2018Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	35113	USD
CY2017Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	30380	USD
CY2018Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	10000000	USD
CY2018Q3	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	113811	USD
CY2018Q3	us-gaap	Long Term Debt LongTermDebt	9917439	USD
CY2018Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	3666667	USD
CY2018Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	4000000	USD
CY2018Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	2333333	USD
CY2018Q3	ctso	Longterm Debt And Final Fee LongtermDebtAndFinalFee	10000000	USD
	ctso	License Period LicensePeriod	P18Y
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	637000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	6414	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	15000	USD
	ctso	Proceeds Of Stock Sale Not Received ProceedsOfStockSaleNotReceived	0	USD
	ctso	Proceeds Of Stock Sale Not Received ProceedsOfStockSaleNotReceived	196417	USD
	ctso	Stock Issued In Connection With Settlement Of Success Fee StockIssuedInConnectionWithSettlementOfSuccessFee	637000	USD
	ctso	Stock Issued In Connection With Settlement Of Success Fee StockIssuedInConnectionWithSettlementOfSuccessFee	0	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	666667	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	5000000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	666667	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	147988	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	1560	USD
	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	13916963	USD
	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	11775046	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1940711	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	181480	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1280706	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	260504	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	16990392	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	17215470	USD
CY2018Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	1200450	shares
CY2018Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Nonvested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested	5635634	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-71620	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	87068	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	7589402	USD
CY2018Q3	ctso	Milestones Percentage MilestonesPercentage	0.375	pure
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	10155170	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5245178	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15400348	USD
	us-gaap	Interest Paid Net InterestPaidNet	667427	USD
	us-gaap	Interest Paid Net InterestPaidNet	407347	USD
	us-gaap	Stock Issued1 StockIssued1	545693	USD
	us-gaap	Stock Issued1 StockIssued1	207608	USD
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28973679	shares
CY2018Q2	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	68791	shares
CY2018Q2	us-gaap	Other Noncash Expense OtherNoncashExpense	637000	USD
CY2018Q3	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	31250	USD
CY2018Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2018Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2018Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31633432	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28973679	shares
CY2018Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31633432	shares
	ctso	Dividend Warrant Exercise Price Adjustment DividendWarrantExercisePriceAdjustment	0	USD
	ctso	Dividend Warrant Exercise Price Adjustment DividendWarrantExercisePriceAdjustment	335731	USD
	us-gaap	Basis Of Accounting BasisOfAccounting	<div style="text-align:left;"><table style="border: none; border-collapse: collapse; margin-bottom: 0.001pt; width: 100%; table-layout: fixed;"><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;width: 18pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: justify; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"> </div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;width: 18pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1.</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: justify; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">BASIS OF PRESENTATION</div></div></div></td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The interim financial statements of CytoSorbents Corporation (the “Company”) have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). In the opinion of management, the Company has made all necessary adjustments, which include normal recurring adjustments, for a fair statement of the Company’s financial position and results of operations for the interim periods presented. Certain information and disclosures normally included in the annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These interim financial statements should be read in conjunction with the audited financial statements and accompanying notes for the year ended December 31, 2017 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (the “SEC”) on March 8, 2018. The results for the three and nine months ended September 30, 2018 and 2017 are not necessarily indicative of the results to be expected for a full year, any other interim periods or any future year or period.</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">As of September 30, 2018, the Company had an accumulated deficit of $164,120,636, which included net losses of $11,808,000 for the nine months ended September 30, 2018 and $5,313,780 for the nine months ended September 30, 2017. The Company’s losses have resulted principally from costs incurred in the research and development of the Company’s polymer technology and selling, general and administrative expenses. The Company intends to continue to conduct significant additional research, development, and clinical study activities which, together with expenses incurred for the establishment of manufacturing arrangements and a marketing and distribution presence and other selling, general and administrative expenses, are expected to result in continuing net losses for the foreseeable future. The amount of future losses and when, if ever, the Company will achieve profitability are uncertain. The Company’s ability to achieve profitability will depend, among other things, on successfully completing the development of its technology and commercial products, obtaining additional requisite regulatory approvals in markets not covered by the CE mark previously received for the Company’s CytoSorb product and for potential label extensions of the current CE mark, establishing manufacturing and sales and marketing arrangements with third parties, and raising sufficient funds to finance the Company’s activities. No assurance can be given that the Company’s product development efforts will be successful, that the Company’s current CE mark will enable it to achieve profitability, that additional regulatory approvals in other countries will be obtained, that any of the Company’s products will be manufactured at a competitive cost and will be of acceptable quality, or that the Company will be able to achieve profitability or that profitability, if achieved, can be sustained. These matters raise substantial doubt about the Company’s ability to continue as a going concern. These consolidated financial statements do not include any adjustments related to the outcome of this uncertainty.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Use of Estimates</div></div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities. Actual results could differ from these estimates. Significant estimates in these financials are the valuation of options granted, and valuation methods used to determine the change in fair value of the down round feature related to certain of the Company’s outstanding warrants.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Concentration of Credit Risk</div></div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company maintains cash balances, at times, with financial institutions in excess of amounts insured by the Federal Deposit Insurance Corporation. Management monitors the soundness of these institutions in an effort to minimize its collection risk of these balances.</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">A significant portion of our revenues are from product sales in Germany. Substantially all of our grant and other income are from grant agencies in the United States. (See Note 4 for further information relating to the Company’s revenue.)</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">As of September 30, 2018, one distributor accounted for approximately 14% of outstanding grants and accounts receivable. As of September 30, 2017, two distributors accounted for approximately 33% of outstanding grants and accounts receivable. As of December 31, 2017, two distributors accounted for approximately 28% of outstanding grants and accounts receivable. For the three and nine months ended September 30, 2018 and 2017, no agency, distributor, or direct customer represented more than 10% of the Company’s total revenue.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Reclassifications Reclassifications	<div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reclassifications</div></div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Certain reclassifications have been made to the September 30, 2017 financial statements in order to conform to the 2018 financial statement presentation. There was no change in the reported amount of the accumulated deficit as a result of these reclassifications.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageRemainingContractualTerm	P0Y
	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageRemainingContractualTerm	P0Y
	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm	P0Y
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	29640061	USD
CY2018Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	20253186	USD
CY2018Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	430358	shares
CY2017Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	4.50
CY2017Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	333333	shares
CY2018Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	80873	USD
CY2017Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	72698	USD
	us-gaap	Other Noncash Expense OtherNoncashExpense	637000	USD
	us-gaap	Other Noncash Expense OtherNoncashExpense	0	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	734308	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	251729	USD
CY2018Q3	ctso	Cytosorb Sales Revenue CytosorbSalesRevenue	5102748	USD
CY2017Q3	ctso	Cytosorb Sales Revenue CytosorbSalesRevenue	3416461	USD
	ctso	Cytosorb Sales Revenue CytosorbSalesRevenue	14693699	USD
	ctso	Cytosorb Sales Revenue CytosorbSalesRevenue	9029606	USD
CY2018Q3	ctso	Other Sales Revenue OtherSalesRevenue	0	USD
CY2017Q3	ctso	Other Sales Revenue OtherSalesRevenue	32200	USD
	ctso	Other Sales Revenue OtherSalesRevenue	87900	USD
	ctso	Other Sales Revenue OtherSalesRevenue	56200	USD
CY2018Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	5102748	USD
CY2017Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	3448661	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	14781599	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	9085806	USD
CY2018Q3	ctso	Revenue From Grant RevenueFromGrant	640225	USD
CY2017Q3	ctso	Revenue From Grant RevenueFromGrant	375638	USD
	ctso	Revenue From Grant RevenueFromGrant	1641464	USD
	ctso	Revenue From Grant RevenueFromGrant	1418237	USD
CY2018Q3	us-gaap	Revenues Revenues	5742973	USD
CY2017Q3	us-gaap	Revenues Revenues	3824299	USD
	us-gaap	Revenues Revenues	16423063	USD
	us-gaap	Revenues Revenues	10504043	USD
CY2018Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2052696	USD
CY2017Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1516864	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5406195	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4253357	USD
CY2018Q3	us-gaap	Gross Profit GrossProfit	3690277	USD
CY2017Q3	us-gaap	Gross Profit GrossProfit	2307435	USD
	us-gaap	Gross Profit GrossProfit	11016868	USD
	us-gaap	Gross Profit GrossProfit	6250686	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1943417	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	643193	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5299475	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1555491	USD
CY2018Q3	us-gaap	Professional Fees ProfessionalFees	416634	USD
CY2017Q3	us-gaap	Professional Fees ProfessionalFees	238303	USD
	us-gaap	Professional Fees ProfessionalFees	1290783	USD
	us-gaap	Professional Fees ProfessionalFees	961444	USD
CY2018Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4040847	USD
CY2017Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3574984	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	14426272	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9771182	USD
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	6400898	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	4456480	USD
	us-gaap	Operating Expenses OperatingExpenses	21016530	USD
	us-gaap	Operating Expenses OperatingExpenses	12288117	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2710621	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2149045	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9999662	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6037431	USD
CY2018Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-185238	USD
CY2017Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-253780	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-1264161	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-497683	USD
CY2018Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-108903	USD
CY2017Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	348546	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-544177	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1221334	USD
CY2018Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-294141	USD
CY2017Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	94766	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1808338	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	723651	USD
CY2018Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-3004762	USD
CY2017Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-2054279	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-11808000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-5313780	USD
CY2018Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-3004762	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-2054279	USD
	us-gaap	Net Income Loss NetIncomeLoss	-11808000	USD
CY2018Q3	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	0	USD
CY2017Q3	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	0	USD
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	0	USD
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	335731	USD
CY2018Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3004762	USD
CY2017Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2054279	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11808000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5649511	USD
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.10
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.21
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	31305620	shares
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	28206437	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	30394326	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27231145	shares
	us-gaap	Net Income Loss NetIncomeLoss	-5313780	USD
CY2018Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	99286	USD
CY2017Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-280078	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1021961	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2905476	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2334357	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11376918	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6335741	USD
CY2018Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	0	USD
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2018-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Registrant Name EntityRegistrantName	Cytosorbents Corp
	dei	Entity Central Index Key EntityCentralIndexKey	0001175151
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Trading Symbol TradingSymbol	CTSO
CY2018Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	31651821	shares
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Small Business EntitySmallBusiness	true

Files In Submission

Name	View Source	Status
0001144204-18-057624-index-headers.html	Edgar Link	pending
0001144204-18-057624-index.html	Edgar Link	pending
0001144204-18-057624.txt	Edgar Link	pending
0001144204-18-057624-xbrl.zip	Edgar Link	pending
ctso-20180930.xml	Edgar Link	completed
ctso-20180930.xsd	Edgar Link	pending
ctso-20180930_cal.xml	Edgar Link	unprocessable
ctso-20180930_def.xml	Edgar Link	unprocessable
ctso-20180930_lab.xml	Edgar Link	unprocessable
ctso-20180930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tv505872_10q.htm	Edgar Link	pending
tv505872_ex31-1.htm	Edgar Link	pending
tv505872_ex31-2.htm	Edgar Link	pending
tv505872_ex32-1.htm	Edgar Link	pending
tv505872_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CTSO
Cytosorbents Corp Stock $ctso

2018 Q4 Form 10-Q Financial Statement

#000114420418057624 Filed on November 06, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTSO Cytosorbents Corp Stock $ctso

2018 Q4 Form 10-Q Financial Statement

#000114420418057624 Filed on November 06, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTSO
Cytosorbents Corp Stock $ctso